Show source-provided references
3. Galimberti, C., Madeo, A., Di Rocco, M., and Fiumara, A. (2018). Mucopolysaccharidoses: Early Diagnostic Signs in Infants and Children, BioMed Central Ltd.
10.1186/s13052-018-0550-5 ↗5. Machnikowska-Sokołowska, M., Myszczuk, A., Wieszała, E., Wieja-Błach, D., Jamroz, E., and Paprocka, J. (2023). Mucopolysaccharidosis Type 1 among Children—Neuroradiological Perspective Based on Single Centre Experience and Literature Review. Metabolites, 13.
10.3390/metabo13020209 ↗7. De Ponti, G., Donsante, S., Frigeni, M., Pievani, A., Corsi, A., Bernardo, M.E., Riminucci, M., and Serafini, M. (2022). MPSI Manifestations and Treatment Outcome: Skeletal Focus. Int. J. Mol. Sci., 23.
10.3390/ijms231911168 ↗9. Blau, N., Duran, M., Gibson, K.M., and Vici, C.D. (2022). Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, Springer International Publishing.
10.1007/978-3-030-67727-5_74 ↗10. Baronio, F., Zucchini, S., Zulian, F., Salerno, M., Parini, R., Cattoni, A., Deodato, F., Gaeta, A., Bizzarri, C., and Gasperini, S. (2022). Proposal of an Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS Ia) among Children with Growth Abnormalities. Medicina, 58.
10.3390/medicina58010097 ↗13. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
16. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy
10.1007/s00431-007-0635-4 ↗18. The Morquio a Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
10.1016/j.ymgme.2013.01.021 ↗19. Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome)
20. Neuroimaging Findings in Patients with Mucopolysaccharidosis: What You Really Need to Know
10.1148/rg.2016150168 ↗22. Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): Presentation, diagnosis and management
10.1007/s10545-013-9586-2 ↗23. Current management options for osteonecrosis of the femoral head: Part 1, diagnosis and nonoperative management
25. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation
10.1016/j.joca.2013.08.001 ↗26. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblings
10.1016/j.ymgme.2012.12.010 ↗27. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: A 3-year follow-up
29. Enzyme-Replacement Therapy in a 5-Month-Old Boy With Attenuated Presymptomatic MPS I: 5-Year Follow-up
10.1542/peds.2009-1728 ↗30. Montanari, G., Candela, E., Baronio, F., Ferrari, V., Biasucci, G., Lanari, M., and Ortolano, R. (2025). Early-Onset Inherited Metabolic Diseases: When Clinical Symptoms Precede Newborn Screening-Insights from Emilia-Romagna (Italy). Children, 12.
10.3390/children12040464 ↗